127 related articles for article (PubMed ID: 24292537)
1. Diagnosis of brainstem involvement in NK/T cell lymphoma.
So JC; Chan KH; Pang AW; Chan JK; Kwong YL
Ann Hematol; 2014 Aug; 93(8):1433-4. PubMed ID: 24292537
[No Abstract] [Full Text] [Related]
2. Extranodal NK/T cell lymphoma, nasal type, presenting with meningeal infiltration in a Caucasian female.
Hildyard C; Sheikh S; Eyre T; Collins G
Br J Haematol; 2013 Dec; 163(5):550. PubMed ID: 24033120
[No Abstract] [Full Text] [Related]
3. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
Ji J; Liu T; Xiang B; Liu W; He C; Chen X; Li J; Chang H; Dai Y; Dong T
Leuk Lymphoma; 2014 Dec; 55(12):2955-7. PubMed ID: 24679007
[No Abstract] [Full Text] [Related]
4. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
[TBL] [Abstract][Full Text] [Related]
5. Combined use of DDGP and IMRT has a good effect on extranodal natural killer/T-cell lymphoma, nasal type.
Zheng Y; Yang C; Liang T; Yang D; Liu Z
Hematol Oncol; 2020 Feb; 38(1):103-105. PubMed ID: 31102421
[No Abstract] [Full Text] [Related]
6. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
8. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma.
Yang J; Shi Y; He X; Dong M; Zhang C; Liu P; Zhou S; Qin Y; Gui L; Yang S; Sun Y
Leuk Lymphoma; 2015 Jul; 56(7):2218-21. PubMed ID: 25563558
[No Abstract] [Full Text] [Related]
10. Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell transplant.
Inoue D; Nagai Y; Takiuchi Y; Nagano S; Arima H; Kimura T; Shimoji S; Mori M; Togami K; Tabata S; Yanagita S; Matsushita A; Nagai K; Maruoka H; Imai Y; Suzuki R; Takahashi T
Leuk Lymphoma; 2010 Apr; 51(4):720-3. PubMed ID: 20233057
[No Abstract] [Full Text] [Related]
11. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
[TBL] [Abstract][Full Text] [Related]
12. Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
Qi F; Chen B; Wang J; Lin X; Qi S; Yang J; Zhou S; Wang S; Gui L; Fang H; Liu P; Song Y; Yang S; Li Y; Dong M
Leuk Lymphoma; 2019 Nov; 60(11):2679-2688. PubMed ID: 31298062
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M
Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454
[TBL] [Abstract][Full Text] [Related]
14. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
Suzuki R
Int J Hematol; 2010 Dec; 92(5):697-701. PubMed ID: 21116747
[TBL] [Abstract][Full Text] [Related]
16. Delayed Diagnosis of a Nasal Type Lymphoma Misdiagnosed as Persistent Sinusitis.
Celentano A; Mascolo M; Cirillo N; De Rosa G; Mignogna MD
J Adolesc Young Adult Oncol; 2017 Jun; 6(2):381-384. PubMed ID: 28061034
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Jaccard A; Gachard N; Marin B; Rogez S; Audrain M; Suarez F; Tilly H; Morschhauser F; Thieblemont C; Ysebaert L; Devidas A; Petit B; de Leval L; Gaulard P; Feuillard J; Bordessoule D; Hermine O;
Blood; 2011 Feb; 117(6):1834-9. PubMed ID: 21123825
[TBL] [Abstract][Full Text] [Related]
18. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
Jung KS; Cho SH; Kim SJ; Ko YH; Kang ES; Kim WS
J Hematol Oncol; 2016 Apr; 9():41. PubMed ID: 27091029
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]